An Adaptive, Phase II, Dose-Finding Clinical Trial Design to Evaluate L-Carnitine in the Treatment of Septic Shock Based on Efficacy and Predictive Probability of Subsequent Phase III Success
Roger Lewis(University of California, Los Angeles), Alan E. Jones(Jackson Memorial Hospital), Scott Berry(Queen's University), Kert Viele(University of Kentucky), Kristine Broglio(Berry & Associates (United States))
Cited by 32
Related Papers
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
|New England Journal of Medicine|2017|5.5k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Critical Care Medicine|2017|3.8k